​

Crescent Biopharma (CBIO) Revenue & Revenue Breakdown

OverviewForecastOwnershipFinancialsChart

Crescent Biopharma Revenue Highlights

00

Main Segment (Y)

Reportable Segment

Crescent Biopharma Revenue by Period

Crescent Biopharma Revenue by Year

DateRevenueChange
2025-12-31-100.00%
2024-12-31--100.00%
2023-12-31$10.00K-86.67%
2022-12-31$75.00K-93.53%
2021-12-31$1.16M-88.59%
2020-12-31$10.16M100.00%
2019-12-31-100.00%
2018-12-31-100.00%
2017-12-31--100.00%
2016-12-31$18.50K-99.91%
2015-12-31$20.07M33.56%
2014-12-31$15.03M276.37%
2013-12-31$3.99M-73.83%
2012-12-31$15.26M300.04%
2011-12-31$3.81M-

Crescent Biopharma generated - in revenue during NA 2025, up 100.00% compared to the previous quarter, and up 0.00% compared to the same period a year ago.

Crescent Biopharma Revenue by Quarter

DateRevenueChange
2026-06-30--100.00%
2026-03-31$1.04M-90.42%
2025-12-31$10.84M100.00%
2025-09-30-100.00%
2025-06-30-100.00%
2025-03-31-100.00%
2024-12-31-100.00%
2024-09-30-100.00%
2024-06-30-100.00%
2024-03-31--100.00%
2023-12-31$10.00K100.00%
2023-09-30-100.00%
2023-06-30-100.00%
2023-03-31-100.00%
2022-12-31-100.00%
2022-09-30--100.00%
2022-06-30$75.00K100.00%
2022-03-31--100.00%
2021-12-31$17.63K-79.64%
2021-09-30$86.56K60857.75%
2021-06-30$142.00-99.99%
2021-03-31$1.06M547.77%
2020-12-31$162.94K-83.71%
2020-09-30$1.00M100.00%
2020-06-30--100.00%
2020-03-31$9.00M100.00%
2019-12-31-100.00%
2019-09-30-100.00%
2019-06-30-100.00%
2019-03-31-100.00%
2018-12-31-100.00%
2018-09-30-100.00%
2018-06-30-100.00%
2018-03-31--

Crescent Biopharma generated - in revenue during Q2 2026, up -100.00% compared to the previous quarter, and up NaN% compared to the same period a year ago.

Crescent Biopharma Revenue Breakdown

Crescent Biopharma Revenue Breakdown by Product

Annual Revenue by Product

Product/ServiceDec 25Dec 24
Reportable Segment$10.84M-
Product-$105.80M

Crescent Biopharma's latest annual revenue breakdown by segment (product or service), as of Dec 25: Reportable Segment (100.00%).

Quarterly Revenue by Product

Product/ServiceJun 26Mar 26Dec 25Sep 25Jun 25
Pharmaceutical Products$29.10M----
Reportable Segment-$1.04M$8.05M$2.79M-
Product---$30.60M$26.80M

Crescent Biopharma's latest quarterly revenue breakdown by segment (product or service), as of Jun 26: Pharmaceutical Products (100.00%).

Crescent Biopharma Peer Comparison by Revenue

TickerCompanyLast Year RevenueLast Quarter Revenue
RCUSArcus Biosciences$247.00M$41.00M
MGNXMacroGenics$149.50M$32.83M
CTMXCytomX Therapeutics$76.20M$1.42M
CGENCompugen$33.46M$2.56M
CLDXCelldex Therapeutics$1.54M$22.00K
CNTXContext Therapeutics--
NBPNovaBridge Biosciences--
CMPXCompass Therapeutics--
CBIOCrescent Biopharma--
ZYMEZymeworks$-27.11M-

CBIO Revenue FAQ

What is Crescent Biopharma’s yearly revenue?

Crescent Biopharma's yearly revenue for 2025 was $0, representing an increase of 100.00% compared to 2024. The company's yearly revenue for 2024 was $0, representing a decrease of -100.00% compared to 2023. CBIO's yearly revenue for 2023 was $10K, representing a decrease of -86.67% compared to 2022.

What is Crescent Biopharma’s quarterly revenue?

Crescent Biopharma's quarterly revenue for Q2 2026 was $0, a -100.00% decrease from the previous quarter (Q1 2026), and a 0% increase year-over-year (Q2 2025). The company's quarterly revenue for Q1 2026 was $1.04M, a -90.42% decrease from the previous quarter (Q4 2025), and a 0% increase year-over-year (Q1 2025). CBIO's quarterly revenue for Q4 2025 was $10.84M, a 100.00% increase from the previous quarter (Q3 2025), and a 0% increase year-over-year (Q4 2024).

What is Crescent Biopharma’s revenue growth rate?

Crescent Biopharma's revenue growth rate for the last 3 years (2023-2025) was -100.00%, and for the last 5 years (2021-2025) was -100.00%.

What are Crescent Biopharma’s revenue streams?

Crescent Biopharma's revenue streams in c 25 are Reportable Segment

What is Crescent Biopharma’s main source of revenue?

For the fiscal year ending Dec 25, the largest source of revenue of Crescent Biopharma was Reportable Segment. This segment made a revenue of $10.84M, representing 100.00% of the company's total revenue.